MARKETING GRANT Sample Clauses

MARKETING GRANT. Client grants Smarsh the limited right to disclose that Client is a customer of Smarsh.
AutoNDA by SimpleDocs
MARKETING GRANT. Licensee will market and sell the product through its independent sales representatives (the “Marketing Grant”). As further consideration for the Marketing Grant, the Licensee shall issue and deliver to the Licensor, on the date hereof, a promissory note in the principal amount of Two Million Dollars ($2,000,000), payable three (3) years from the date of issuance.
MARKETING GRANT. 2.1. BTI hereby grants to BSD the exclusive right to promote, market, and offer to sell and distribute the Product in the Field in the Territory, and BSD hereby accepts from BTI the exclusive right to promote, market and offer to sell in the Field in the Territory and agrees to act in that capacity, upon and subject to all terms and conditions set forth in this Agreement. BTI shall not, directly or indirectly, sell Product in the Field in the Territory except to buyers identified to it by BSD and subject to the terms and conditions of this Agreement. The Steering Committee shall have the authority to set list pricing for Product for each customer or geographic market provided: (a) Initially the direct to consumer pricing for “SUGARDOWN®” trademarked product in tablet form through Website sales shall be $39.99 per Unit plus reasonable shipping and handling; (b) Such initial pricing as provided in 2.1(a) shall be subject to change to such price as determined by the Steering Committee (as described in Section 4 below) in its judgment to be best suited for the circumstances of the marketplace and in light of costs of production and other relevant factors. (c) BSD shall be the exclusive operator of the Website or Websites (the “Website”) providing technical information, marketing and sales materials and direct sales to the trade, commercial users and to consumers and utilizing the “SUGARDOWN” trademark. BTI shall own the Website and the domain. 2.2. Subject to the terms of this Agreement, the rights provided to BSD under Section 2.1 above shall be an exclusive, paid-up license under the BTI Patents and Trademarks to promote, market, and offer to sell and distribute the Product in the Field in the Territory. (a) BSD acknowledges and agrees that the rights granted pursuant to this Agreement are limited to the Field and the Territory and confer no rights upon BSD with respect to the promotion, marketing, offers to sell and sale and distribute of the Product outside the Field and outside the Territory, and nothing in this Agreement shall restrict BTI from selling Product to any other Third Party and outside the Territory or Field.
MARKETING GRANT. 2.1 ADS hereby appoints and grants to Parkway a non-exclusive license and right to market, sell and promote the system throughout the United States. Parkway does hereby accept such appointment and grant on the terms and conditions as herein set forth and agrees to use its best efforts in performing its marketing services. 2.2 ADS agrees that the system being marketed by Parkway meets or exceeds the functional standards of the current production release of the system, or a release containing already agreed upon and planned functional modifications. It shall be the duty of Parkway to obtain a current functional specification of the system prior to making any representations to a prospective licensee. 2.3 Parkway acknowledges and agrees that ADS is the sole and exclusive owner of any and all rights, title, and interest in and to the system including any copyright and that all components and services licensed, marketed or sold by Parkway shall dearly identify ADS as the owner and licensor of the system. 2.4 Parkway acknowledges that ADS will work directly with all prospective clients interested in licensing the system, with neither party having any obligation to Parkway beyond the fees specified in Exhibit B of this agreement. ADS's interaction with the client will be necessary to fulfill the service offerings of ADS as described in Exhibit A of this agreement
MARKETING GRANT. Subject to the terms and conditions of this Agreement, Licensors hereby further grant to Licensee the perpetual, exclusive right and license, under all intellectual properly and other ownership rights applicable to the Technology and/or the Products, to display and market the Products to the end users of said Products (the "Marketing Grant"). This exclusive grant is to be worldwide in geographic scope. Licensee will market and sell the product in the manner it, in its sole discretion, deems most appropriate. As the Product is sold, Licensee will buy the Product from Licensors. Licensors will provide Licensee with information showing the current pricing of the Products as advertised by their company to other customers, updated as said pricing changes from time to time, and will charge Licensee 70% of the listed price for the Products on volume purchases. Licensors agree that, when they learn of interest that any potential customer has expressed in the Products, the Licensors will immediately advise Licensee of the potential customer's identity, the nature of the customer's interest, the amount of the potential contract price and the basis for determining that contract price. Licensee will then have ten (10) days from the date of notice to determine whether, in its sole discretion, it desires to market and sell the Products to the potential customer. If Licensee does so desire, Licensee will proceed with the marketing of the Product, with Licensors providing reasonable assistance to Licensee in completing the sale. If Licensee does not so desire. Licensee will provide Licensors with written notice of its refusal to market and sell the product to the potential customer, and Licensors will then be free to engage other service providers to market and sell the Product to that potential customer.

Related to MARKETING GRANT

  • Marketing Plan The MCOP shall submit an annual marketing plan to ODM including all planned activities for promoting membership in or increasing awareness of the MCOP. The marketing plan submission shall include an attestation by the MCOP that the plan is accurate and is not intended to mislead, confuse, or defraud the eligible individuals or ODM.

  • Joint Commercialization Committee (i) The JCC shall oversee Commercialization of JAK Licensed Products in the Field worldwide. As soon as practicable following the Effective Date (but in no event more than thirty (30) days following the Effective Date), each Party shall designate its initial three (3) representatives on the JCC. The JCC shall be composed of appropriate and key executives of Novartis together with an equal number of appropriate and key executives from Incyte. Novartis and Incyte shall each appoint a person from among its representatives on the JCC to serve as the co-chairperson of the JCC. The co-chairpersons shall not have any greater authority than any other representative on the JCC and shall conduct the following activities of the JCC: (A) calling meetings of the JCC; (B) preparing and issuing minutes of each such meeting within thirty (30) days thereafter; (C) preparing and circulating an agenda for the upcoming meeting; and (D) ensuring that any decision-making delegated to the JCC is carried out in accordance with Section 3.5. (ii) The JCC shall be responsible for: (A) overseeing, reviewing and coordinating the Commercialization of JAK Licensed Products in the Field worldwide; (B) developing and overseeing the Global Branding Strategy; (C) setting overall strategic objectives and plans related to Commercialization of JAK Licensed Products in the Field worldwide; (D) reviewing, commenting on and approving the Promotional Plan; (E) reviewing Commercialization issues for JAK Licensed Products in the Field in the Novartis Territory that will have an impact on Commercialization of JAK Licensed Products in the Field in the Incyte Territory; (F) reviewing Commercialization issues for JAK Licensed Products in the Field in the Incyte Territory that will have an impact on Commercialization of JAK Licensed Products in the Field in the Novartis Territory; (G) providing a forum for the Parties to discuss the Commercialization of JAK Licensed Products in the Field worldwide; and (H) such other responsibilities as may be assigned to the JCC pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to time.

  • Commercialization Plan At such times as the JGC will deem appropriate, the JGC will direct the Parties to mutually prepare a Worldwide Commercialization Plan, and the JGC will review and approve such initial Worldwide Commercialization Plan. Thereafter, the JGC will have one or the other Party (or both) update the Worldwide Commercialization Plan each calendar year, and the JGC will review and approve any such update or any other amendment to the Worldwide Commercialization Plan. Notwithstanding anything in this CCPS Agreement to the contrary, the Parties acknowledge and agree that (i) Bluebird may decline to perform any Commercialization activity proposed to be conducted by Bluebird in the Worldwide Commercialization Plan (other than Manufacturing of Vectors and associated Payloads), and (ii) the Worldwide Commercialization Plan will not include, and Bluebird will have no obligation to perform, any such Commercialization activity that Bluebird has declined to perform, provided that once Bluebird has agreed to perform a Commercialization activity, it will be obligated to perform, and cannot decline to perform, such activity. In addition, either Party may request at any time that the JGC consider and approve other updates to the Worldwide Commercialization Plan. Further: (a) The JGC will set the required form and contents of the Worldwide Commercialization Plan. The Worldwide Commercialization Plan will reflect a singular marketing and sales approach worldwide, and will specify, among other things, the number of sales reps in the U.S. for each Party, allocation of regions in the U.S. for each Parties’ sales force, creation of marketing materials, planning for conferences, and other marketing activities. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. (b) Neither Party (itself or by or through any others, including any Affiliates or Sublicensees) will take any material action regarding the Commercialization of Licensed Product unless described in the Worldwide Commercialization Plan or approved by the JGC. (c) All Commercialization of Licensed Product for U.S. Administration will be conducted under the supervision of the JGC and as part of the U.S. Development & Commercialization Program. (d) Celgene will have final decision making authority for all Commercialization activities worldwide, including timing of launch and pricing and the Worldwide Development Plan.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Marketing Rights Neither the Company nor any of its Subsidiaries have granted rights to license, market, or sell its products or services to any other Person and is not bound by any agreement that affects the Company’s (or any Subsidiary’s) exclusive right to develop, distribute, market or sell its products or services.

  • Employee Development The Employer may provide employees the opportunity to participate in appropriate seminars, workshops or short courses. When possible and appropriate the Employer will provide to all staff information on seminars, workshops or short courses by posting a notice on the Employer’s internal web site.

  • Program Development NWESD agrees that priority in the development of new applications services by XXXXX shall be in accordance with the expressed direction of the XXXXX Board of Directors operating under their bylaws.

  • Non-Marketing Purposes This Childcare Website greatly respects your privacy. We do maintain and reserve right to contact you if needed for non-marketing purposes (such as bug alerts, security breaches, account issues, and/or changes in This Childcare Website’s products and services). In circumstances, we may use our website, newspapers, or other public means to post a notice. This Childcare Website is not directed to, and does not knowingly collect personal identifiable information from, children under the age of thirteen (13). If it is determined that such information has been inadvertently collected on anyone under the age of thirteen (13), we shall immediately take the necessary steps to ensure that such information is deleted from our system’s database, or in the alternative, that verifiable parental consent is obtained for the use and storage of such information. Anyone under the age of thirteen (13) must seek and obtain parent or guardian permission to use this website.

  • Marketing Plans Contractor and the Exchange recognize that Enrollees and other health care consumers benefit from efforts relating to outreach activities designed to increase heath awareness and encourage enrollment. The parties shall share marketing plans on an annual basis and with respect to periodic updates of material changes. The marketing plans of each of the Exchange and Contractor shall include proposed marketing approaches and channels and shall provide samples of any planned marketing materials and related collateral as well as planned, and when completed, expenses for the marketing budget. The Contractor shall include this information for both the Exchange and the outside individual market. The Exchange shall treat all marketing information provided under this Section as confidential information and the obligation of the Exchange to maintain confidentiality of this information shall survive termination or expiration of this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!